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ABSTRACT
This paper primarily summarizes the work done
under the guidance of Dr. Bruce Chabner in 1975 and
1976. During these years I studied the role of drug con-
centration, duration of exposure, and endogenous
metabolites in determining methotrexate (MTX) cyto-
toxicity to the bone marrow stem cell (CFU-C). We
found that the rate of loss of CFU-C during continuous
intravenous infusion of methotrexate was related to
the duration of exposure until the nadir in cell count
was reached at 24 hours. Depletion of nucleated cells
was mitigated, probably as a result of recruitment of
previously uncommitted precursor cells to CFU-C,
even while the MTX infusion was continued up to 48
hours. In vitro it was shown that methotrexate and leu-
covorin were transported competitively in the CFU-C,
which was in clear contrast with rescue agents such as
thymidine and nucleoside analogs. After my training
my work has continued in close contact with Dr.
Chabner, while the scope of both our interests broad-
ened to include the field of multidrug resistance
(MDR). My own interest focused on functional studies
in MDR. The Oncologist 1996;1:232-233
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In December 1974 I arrived at the medical branch of the
National Cancer Institute. Unfortunately, my host had taken
a job elsewhere, so I felt I was left in the lurch in a huge
institute in a foreign country. It was clear to me that I had
to put together my own program. At that time I had never
heard of Bruce Chabner. I sat down for a full week in the
library studying bone marrow physiology and stem cell cul-
ture. At that same time I was intrigued by the introduction
into the clinic of high-dose methotrexate (MTX) as a new
treatment for osteosarcoma. My second topic to study was
the preclinical pharmacology of this antimetabolite which
seemed to be making furor. So another week was spent in
the library to get acquainted with the pharmacology of
MTX. The days thereafter were spent putting the two sub-
jects together and preparing a workplan, which I presented
to Joan Bull on the 3rd floor.
As I needed mice and a spectrophotometer, I intruded
on the 6th floor and introduced myself to Dan Zaharko. I
was offered space in the animal room and a bench next to a
spectrophotometer. On a day in February, 1975, while mea-
suring mouse plasma samples of MTX, I bumped into
Bruce Chabner, who kept observing me working in the
Pharmacology Branch. He asked for my research plan and
was truly interested in my ideas. Soon thereafter we dis-
cussed my plan in detail. It seemed that the potential clini-
cal impact of my work was constantly in his focus. In short,
my project would study the effect of MTX concentration
and its duration of exposure on the bone marrow stem cell,
both in vitro and in vivo. This was the beginning of a very
intense collaboration with Bruce.
The difficult early days proved to be the start of a most
exciting year, in fact the most exciting one in my research
career. This was a year without any administrative headaches,
without responsibilities for running any department. In order
to study the effect of constant exposure of MTX on bone mar-
row CFU-C, I used a glass tube device developed by Dan
Zaharko. I am still very grateful to him. Indeed, he also had a
very critical look at the data I generated. The infusion device
permitted s.c. infusion of MTX into mice at a constant rate.
Physical characteristics of devices ranging in size were stud-
ied. Plateau plasma concentrations of MTX (1 × 10–8 M to 
1 × 10–5 M) achieved from infusion rates varying over three
orders of magnitude (<1 to >100 µg/h) were studied and eval-
uated in terms of toxicity and pharmacokinetic behavior of
this drug. 
The effects of exposure of bone marrow to specific MTX
concentrations were studied by constant infusion of the drug
into mice. The residual marrow nucleated cell count was
determined in mice at specific intervals. In vitro culture of
CFU-C was also performed in these mice. Duration of expo-
sure varied from 12 h to 72 h.  Plateau plasma MTX concen-
trations were studied in the range from 10–8 to 10–5 M.
Unexpectedly, the total number of nucleated cells per femur
fell to a plateau of 30% of control for all drug concentrations
studied. The nadir was reached earliest with the highest drug
concentrations. The percentage of CFU-C per fixed number
of nucleated cells plated increased at 48-h infusions, com-
pared to the percentage at 24 h. This increase was seen at all
plasma concentrations studied. The total number of CFU-C at
plasma MTX concentrations above 10–6 M decreased in the
first 24 h, but then the number significantly increased between
24 h and 48 h. In contrast, no change was observed in CFU-
C per femur between 24 h and 48 h during constant infusion
at plasma concentrations below 10–6 M. Constant exposure to
10–5 M MTX produced a rapid decrease in total nucleated
cells to 35% at 12 h, which remained at approximately this
level throughout 48 h of drug infusion. A decrease in the num-
ber of both CFU-C and CFU-S per femur was observed,
which paralleled the drop in nucleated cells during the first 24
h. However, in contrast to the increase in CFU-C during the
next 24 h, an additional drop in the number of CFU-S was
observed at this high concentration. These data indicated a
self-limited cell kill of nucleated bone marrow cells, and sug-
gested recruitment of CFU-C from the CFU-S pool between
24 h and 48 h of infusion despite continued MTX infusion. 
Thereafter, the cytotoxic effect of MTX for mouse bone
marrow cells was studied by in vitro culture of granulocyte
precursor cells (CFU-C). The formation of colonies was
inhibited to 50% of control by 10–8 M MTX. Further increases
in MTX concentration rapidly abolished colony formation by
CFU-C. The potential of leucovorin and nucleosides to rescue
the CFU-C from MTX toxicity was studied. Toxicity of 10–7
M MTX was completely reversed by equimolar concentra-
tions of leucovorin, but with higher MTX concentrations,
relatively more leucovorin was required. While MTX was
rescued by leucovorin, rescue of the toxic effect of 10–4 M
MTX by 10–3 M leucovorin was not observed. In contrast to
the rescue by leucovorin, toxicity of all MTX concentrations
up to 10–4 M was completely prevented by 10–5 M thymidine
with 10–5 M adenosine, inosine, or hypoxanthine. Single
nucleosides of thymidine with guanosine were ineffective,
as were lower concentrations (≤10–6 M) of the effective
combinations. Thus, while leucovorin reversed the MTX
toxicity to CFU-C competitively, rescue by nucleosides was
noncompetitive. 
Since my return to The Netherlands in 1976 my scientific
work continued to focus on cellular pharmacology. In the
beginning, I performed several in vitro experiments on L1210
cells. Grossly, the findings were pretty much in agreement
with the in vitro observations for the CFU-Cs. In those days
Al Leyva, who was recommended by Dr. Chabner, joined my
group in Utrecht. In the eighties, after moving with my group
to Amsterdam, the MTX work made way for 5 fluorouracil
and PALA. The type of studies did not change, however.
Studies now focused on the target enzymes. Cellular resis-
tance in the MDR field gradually came into focus, a field into
which both Bruce and I moved. Because of the potential pres-
ence of a number of cellular proteins keeping the drugs from
reaching their targets, my group switched to functional
assays. We first applied acute myeloid leukemia as a model,
but more recently we are attempting to dissociate solid tumors
to perform similar functional studies. However, the tumor
stroma is making such an approach extremely difficult. In the
clinic we both embarked on MDR reverting trials. Our trials
with reverting agents in solid tumors have been quite disap-
pointing. At this year’s AACR, Bruce will be organizing a
symposium on controversies in this field, which without any
doubt will be of great interest. Part of the discussion will be
the lack of predictiveness of preclinical models of drug
resistance for the clinic. 
It may ultimately appear that we have been focusing too
much on Pgp as a resistance marker, while reality is closer
to Pgp being a marker for aggressiveness. Pgp might appear
to be an ATP-dependent pump for endogenous compo-
nents. If true, one would expect its affinity for such com-
pounds to be higher, and with a higher concentration of the
biological products at the pump than of any reverter admin-
istered. This would leave a very narrow window for revert-
ers and for clinical trials to be successful. The situation may
prove slightly different for acute leukemia and myeloma
where the extracellular concentration of the reverter may be
sufficient to compete with endogenous products.
Bruce Chabner and Dan Longo joined me as editors of
the successful Cancer Chemotherapy Annual. Moreover, 
I have greatly appreciated Bruce’s co-chairmanship of the
NCI/EORTC New Drug Symposia during the past 10 years.
In conclusion, more than 20 years have passed since Bruce
Chabner triggered my interest in the field of pharmacology
of antineoplastic agents. Both our research interests were ini-
tially dominated by the antimetabolites. Thereafter, there was
a broadening of the scope with the introduction of the MDR
research. As with his other disciples, I have maintained close
contact with him despite our physical distance, exchanging
data on a routine basis.
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